200 related articles for article (PubMed ID: 36301933)
61. Efficacy of dolutegravir + lamivudine q.d. with food in people with TB/HIV using a rifampicin-based regimen: A retrospective observational case series.
Dou Y; Lu R; Su L; Lan K; Meng Z; Qin S; Huang L; Huang W; Xu Y; Lv Y; Wen Y; Lan S; Zuo Y; Zhang Y
HIV Med; 2024 Jun; 25(6):754-758. PubMed ID: 38494173
[TBL] [Abstract][Full Text] [Related]
62. Three-year durable efficacy of dolutegravir plus lamivudine in antiretroviral therapy - naive adults with HIV-1 infection.
Cahn P; Sierra Madero J; Arribas JR; Antinori A; Ortiz R; Clarke AE; Hung CC; Rockstroh JK; Girard PM; Sievers J; Man CY; Urbaityte R; Brandon DJ; Underwood M; Pappa KA; Curtis L; Smith KY; Gartland M; Aboud M; van Wyk J; Wynne B
AIDS; 2022 Jan; 36(1):39-48. PubMed ID: 34534138
[TBL] [Abstract][Full Text] [Related]
63. No Changes in Human Immunodeficiency Virus (HIV) Suppression and Inflammatory Markers in Cerebrospinal Fluid in Patients Randomly Switched to Dolutegravir Plus Lamivudine (Spanish HIV/AIDS Research Network, PreEC/RIS 62).
Tiraboschi JM; Rojas J; Zetterberg H; Blennow K; Niubo J; Gostner J; Navarro-Alcaraz A; Piatti C; Fuchs D; Gisslén M; Rigo-Bonnin R; Martinez E; Podzamczer D
J Infect Dis; 2021 Jun; 223(11):1928-1933. PubMed ID: 33049035
[TBL] [Abstract][Full Text] [Related]
64. Switching from a regimen containing abacavir/lamivudine or emtricitabine/tenofovir disoproxil fumarate to emtricitabine/tenofovir alafenamide fumarate does not affect central nervous system HIV-1 infection.
Yilmaz A; Mellgren Å; Fuchs D; Nilsson S; Blennow K; Zetterberg H; Gisslén M
Infect Dis (Lond); 2019; 51(11-12):838-846. PubMed ID: 31556765
[No Abstract] [Full Text] [Related]
65. Abacavir/lamivudine/dolutegravir single tablet regimen in patients with human immunodeficiency virus and end-stage renal disease on hemodialysis.
Michienzi SM; Schriever CA; Badowski ME
Int J STD AIDS; 2019 Feb; 30(2):181-187. PubMed ID: 30381029
[TBL] [Abstract][Full Text] [Related]
66. Switching to tenofovir/emtricitabine from abacavir/lamivudine in HIV-infected adults with raised cholesterol: effect on lipid profiles.
Behrens G; Maserati R; Rieger A; Domingo P; Abel F; Wang H; Pearce G
Antivir Ther; 2012; 17(6):1011-20. PubMed ID: 22910324
[TBL] [Abstract][Full Text] [Related]
67. Tenofovir, emtricitabine, lamivudine and dolutegravir concentrations in plasma and urine following drug intake cessation in a randomized controlled directly observed pharmacokinetic trial to aid point-of-care testing.
Else LJ; Dickinson L; Edick S; Zyhowski A; Ho K; Meyn L; Dilly-Penchala S; Thompson B; Shaw V; Khoo S; Brand RM
J Antimicrob Chemother; 2024 Jul; 79(7):1597-1605. PubMed ID: 38758205
[TBL] [Abstract][Full Text] [Related]
68. Brief Report: Improvement in Metabolic Health Parameters at Week 48 After Switching From a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen to the 2-Drug Regimen of Dolutegravir/Lamivudine: The TANGO Study.
van Wyk J; Ait-Khaled M; Santos J; Scholten S; Wohlfeiler M; Ajana F; Jones B; Nascimento MC; Tenorio AR; Smith DE; Wright J; Wynne B
J Acquir Immune Defic Syndr; 2021 Jun; 87(2):794-800. PubMed ID: 33587500
[TBL] [Abstract][Full Text] [Related]
69. Efficacy, Convenience, Safety and Durability of DTG-Based Antiretroviral Therapies: Evidence from a Prospective Study by the Italian MaSTER Cohort.
Fusco P; Nasta P; Quiros-Roldan E; Tondinelli A; Costa C; Fornabaio C; Mazzini N; Prosperi M; Torti C; Carosi G
Viruses; 2023 Apr; 15(4):. PubMed ID: 37112904
[No Abstract] [Full Text] [Related]
70. Dolutegravir, abacavir and lamivudine as HIV therapy.
Fernandez-Montero JV; Barreiro P; Labarga P; De Mendoza C; Soriano V
Expert Opin Pharmacother; 2014 May; 15(7):1051-7. PubMed ID: 24754315
[TBL] [Abstract][Full Text] [Related]
71. Bictegravir versus dolutegravir, each with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection: a randomised, double-blind, phase 2 trial.
Sax PE; DeJesus E; Crofoot G; Ward D; Benson P; Dretler R; Mills A; Brinson C; Peloquin J; Wei X; White K; Cheng A; Martin H; Quirk E
Lancet HIV; 2017 Apr; 4(4):e154-e160. PubMed ID: 28219610
[TBL] [Abstract][Full Text] [Related]
72. Efficacy, durability, and tolerability of dolutegravir/lamivudine and dolutegravir/rilpivirine for the treatment of HIV in a real-world setting in Belgium.
Nasreddine R; Yombi JC; Darcis G; Florence E; Allard SD; De Scheerder MA; Henrard S; Demeester R; Messiaen P; Ausselet N; Loeckx M; Delforge M; De Wit S;
HIV Med; 2023 Mar; 24(3):267-278. PubMed ID: 35938381
[TBL] [Abstract][Full Text] [Related]
73. Tolerability of bictegravir/tenofovir alafenamide/emtricitabine versus dolutegravir/lamivudine as maintenance therapy in a real-life setting.
Rocabert A; Borjabad B; Berrocal L; Blanch J; Inciarte A; Chivite I; Gonzalez-Cordon A; Torres B; Ambrosioni J; Martinez-Rebollar M; Laguno M; De La Mora L; Foncillas A; Sempere A; Rodriguez A; Solbes E; Llobet R; Miro JM; Mallolas J; Blanco JL; De Lazzari E; Martinez E
J Antimicrob Chemother; 2023 Dec; 78(12):2961-2967. PubMed ID: 37875023
[TBL] [Abstract][Full Text] [Related]
74. Immunovirological outcome and HIV-1 DNA decay in a small cohort of HIV-1-infected patients deintensificated from Abacavir/Lamivudine/Dolutegravir to Lamivudine plus Dolutegravir.
Lanzafame M; Nicole S; Rizzardo S; Piacentini D; Chiesi S; Lattuada E; Diani E; Carelli M; Vento S; Gibellini D
New Microbiol; 2018 Oct; 41(4):262-267. PubMed ID: 30311623
[TBL] [Abstract][Full Text] [Related]
75. Comparison of the efficacy, safety and durability of a switch to co-formulated RPV/TDF-TAF/FTC or DTG/ABC/3TC in virologically-suppressed HIV-1-infected patients in a single Italian centre: a cohort data analysis.
Lagi F; Botta A; Kiros ST; Meli M; Borchi B; Cavallo A; Pozzi M; Bartoloni A; Sterrantino G
Int J Antimicrob Agents; 2022 Jan; 59(1):106465. PubMed ID: 34699933
[TBL] [Abstract][Full Text] [Related]
76. Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection (ARIA): week 48 results from a randomised, open-label, non-inferiority, phase 3b study.
Orrell C; Hagins DP; Belonosova E; Porteiro N; Walmsley S; Falcó V; Man CY; Aylott A; Buchanan AM; Wynne B; Vavro C; Aboud M; Smith KY;
Lancet HIV; 2017 Dec; 4(12):e536-e546. PubMed ID: 28729158
[TBL] [Abstract][Full Text] [Related]
77. Impact of resistance mutations on efficacy of dolutegravir plus rilpivirine or plus lamivudine as maintenance regimens: a cohort study.
Gagliardini R; Baccini M; Modica S; Montagnani F; Zanelli G; Borghetti A; Dreassi E; Lombardi F; Pecorari M; Borghi V; Callegaro A; Micheli V; Lodi MA; Rossetti B; Zazzi M;
J Glob Antimicrob Resist; 2022 Mar; 28():274-281. PubMed ID: 35092828
[TBL] [Abstract][Full Text] [Related]
78. Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials.
Cahn P; Madero JS; Arribas JR; Antinori A; Ortiz R; Clarke AE; Hung CC; Rockstroh JK; Girard PM; Sievers J; Man C; Currie A; Underwood M; Tenorio AR; Pappa K; Wynne B; Fettiplace A; Gartland M; Aboud M; Smith K;
Lancet; 2019 Jan; 393(10167):143-155. PubMed ID: 30420123
[TBL] [Abstract][Full Text] [Related]
79. Long-term data on the efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multi-centre cohort of HIV-1-infected, virologically suppressed patients.
Baldin G; Ciccullo A; Rusconi S; Capetti A; Sterrantino G; Colafigli M; d'Ettorre G; Giacometti A; Cossu MV; Borghetti A; Gennari W; Mussini C; Borghi V; Di Giambenedetto S
Int J Antimicrob Agents; 2019 Dec; 54(6):728-734. PubMed ID: 31521809
[TBL] [Abstract][Full Text] [Related]
80. Bictegravir/Emtricitabine/Tenofovir Alafenamide: A Review in HIV-1 Infection.
Deeks ED
Drugs; 2018 Nov; 78(17):1817-1828. PubMed ID: 30460547
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
